Treatment of SFA lesions with Drug-Eluting technologies
SUSTAINED RELEASE – SUPERIOR RESULTS

Watch the video now
The Growing Evidence Base on Drug Eluting Technologies: A new Focus on Drug Eluting Stent
- Results of the IMPERIAL Randomized Controlled Trial of Eluvia vs Zilver PTX
- Drug Eluting Stent in Peripheral Artery Disease, Critical Limb Ischemia and Below The Knee indications
Boston Scientific is the only company investing in a complete portfolio of drug-eluting therapies, designed to revolutionize the field, as well as ground-breaking pre-clinical and clinical research that are helping define how to better use the technologies. Our commitment is to bring forward innovative therapies that can make a difference in the lives of patients, and our foundation of more than 15 years of design and development has established our clinical leadership.
DID YOU KNOW
Products Overview
technology.




